Has any other histologic type of skin cancer other than invasive squamous cell carcinoma as the primary disease under study, eg, basal cell carcinoma that has not been definitively treated with surgery or radiation, Bowen's disease, Merkel cell carcinoma (MCC), melanoma.
Patient has a history of new diagnosis or treatment of cancer other than malignant glioma within five years prior to start of the study, except for basal cell carcinoma or squamous cell carcinoma.
Active malignancy (excluding localized squamous cell or basal cell carcinoma of the skin)
Prior history of malignancy other than HCC, dermatologic basal cell or squamous cell carcinoma
Subjects diagnosed with another cancer in the past  years; excluding basal cell carcinoma or squamous cell carcinoma, of skin which were completely cured by resection
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigators opinion will shorten survival to less than  year
Previously diagnosed malignancy excluding basal or squamous cell carcinoma of the skin (unless disease-free for  years or more)
History of another malignancy within -years of date of except history of (h/o) basal cell or squamous cell carcinoma of skin or polycythemia vera or essential thrombocythemia
Noninvasive basal cell and squamous cell skin carcinoma
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
No active second malignancy with the exception of basal or squamous cell carcinoma of the skin
Skin cancer other than actinic keratosis, basal cell carcinoma, and squamous cell carcinoma in situ in the field of RT
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigators opinion will shorten survival to less than  year.
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigators opinion will shorten survival to less than  year.
History of prior malignancy that has not been in remission for > years, with the exception of basal cell or squamous cell carcinoma.
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
Patients must not have a different active malignancy, except for skin basal cell carcinoma, skin squamous cell carcinoma and cervical intraepithelial neoplasia
Patients with an active second invasive malignancy, other than basal cell carcinoma of the skin.
Patients with primary effusion lymphoma or other concurrent malignancy, except for basal cell carcinoma or squamous carcinoma of the skin or in situ cervical or anal dysplasia
Patients may have had a prior diagnosis of cancer if it has been >  years since their last treatment (with the exception of squamous cell carcinoma or basal cell carcinoma of the skin or cervical intraepithelial neoplasia)
Patients with a history of any active malignancy requiring on-going treatment, except basal cell carcinoma or squamous cell carcinoma of the skin
Concurrent active or measurable malignancies, except basal cell carcinoma or squamous cell carcinoma of the skin
Have other concurrent malignancy (subjects with treated squamous cell carcinoma of the skin or basal cell carcinoma of the skin may be included), evidence of extrahepatic cancer from their primary malignancy, or ongoing, medically significant active infection.
Subjects with active other tumors, except early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN)
No active second malignancy except for basal cell carcinoma of the skin
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than  year
Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin)
treated basal-cell or squamous cell skin carcinoma
Any type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or intracerebral metastasis and acute leukemia);
Active second invasive malignancy, other than basal cell carcinoma of the skin.
Basal cell carcinoma (BCC)
Non-invasive basal cell or squamous cell skin carcinoma.
Previously diagnosed malignancy excluding basal or squamous cell carcinoma of the skin (unless disease-free for  years or more)
Concurrent malignancy requiring active treatment, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ
Patients with a secondary primary cancer (excluding baso/squamous cell carcinoma of skin) within  year will be excluded
History of (H/o) another malignancy within -years of date of HCT except h/o basal cell or squamous cell carcinoma of skin or PV or ET
Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
Concurrent malignancy (other than squamous cell carcinoma [SCC] or basal cell carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last  years
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Basal or squamous cell carcinoma of the skin
History of other malignancy, with the exception of squamous cell carcinoma of the skin, basal cell carcinoma of the skin, cervical intraepithelial neoplasia, or other malignancies that have been in remission for at least  years
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
benign basal cell carcinoma
A prior invasive malignant disease within five years except for skin cancer (squamous cell or basal cell carcinoma)
Non-invasive basal cell or squamous cell skin carcinoma.
Treatment of other invasive carcinomas within the last five years with greater than % risk of recurrence at time of eligibility screening; carcinoma in-situ and basal cell carcinoma/ squamous cell carcinoma of the skin are allowed
Patients with basal cell carcinoma or squamous cell carcinoma.
Any additional solid tumour or hematologic malignancy during the past  years except T skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine/cervical cancer.
Diagnosis of cancer that in not considered cured, except basal cell carcinoma (BCC) of skin
Basal or squamous cell carcinoma of the skin
Histopathologic diagnosis of basal or squamous cell carcinoma
Patients who are receiving therapy for another active malignancy are NOT eligible for participation\r\n* The exception to this is squamous cell carcinoma or basal cell carcinoma of the skin
Treatment for other invasive carcinomas within the last five years who are at greater than % risk of recurrence at time of eligibility screening; carcinoma in-situ and basal cell carcinoma/squamous cell carcinoma of the skin are allowed
Note: patients with early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin or cervical intraepithelial neoplasia are eligible for enrollment
Treatment for other invasive carcinomas within the last five years with greater than % risk of recurrence at time of eligibility screening; carcinoma in-situ and basal cell carcinoma/squamous cell carcinoma of the skin are allowed
Current coexisting malignancy other than basal cell carcinoma
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than  year
Recent (within  years) history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin
Have prior history of other malignancies, excluding basal cell carcinoma or squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Basal cell carcinoma of the skin.
Squamous cell carcinoma of the skin.
Cancer, other than basal-cell or squamous-cell carcinoma of the skin;
Diagnosis for other invasive carcinomas (except basal cell carcinoma/squamous cell carcinoma of the skin) within the last five years unless deemed by the investigator to be at low risk for recurrence of that malignancy; carcinoma in-situ is allowed
Non-invasive basal cell or squamous cell skin carcinoma.
An active second primary malignancy with the exception of basal cell or squamous cell skin carcinoma
History of another malignancy within -years of date of HCT except history of basal cell or squamous cell carcinoma of skin or PV or ET
Does the patient have a history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than five years?
Any metastatic basal cell carcinoma
History of another malignancy within  years, except cured basal cell carcinoma of the skin
history of prior malignancy, excluding basal or squamous cell carcinoma of the skin, with an expected survival of less than  years.
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigators opinion will shorten survival to less than  year
Past history of a cancer diagnosis (excluding basal cell skin carcinoma)
Prior malignancy (other than basal cell/squamous cell carcinoma of the skin, in-situ cervical carcinoma or superficial transitional cell bladder carcinoma) diagnosed and/or treated within three years of study entry
Have not been diagnosed with a prior cancer within the recent  years, except basal or squamous cell skin carcinoma
Men with a prior diagnosis of cancer <  years ago, excluding basal cell carcinoma and/or squamous cell carcinoma
Other co-existing invasive malignancies (with the exclusion of basal cell carcinoma or skin squamous cell carcinoma) diagnosed during the last  years before randomization
Basal or squamous cell carcinoma of the skin
Basal cell carcinoma of the skin
Squamous cell carcinoma of the skin
Prior history of any other malignancy within  years, other than skin basal cell carcinoma
History of other malignancy (with the exception of squamous cell or basal cell carcinoma of the skin) diagnosed within the last  years